Replicate Bioscience, Inc.

The Power of RNA Amplified
Pioneering novel self-replicating RNA (srRNA) technology for widespread use.

[Replicate Bioscience, Inc. @Replicate_Bio]

What makes srRNA different?

Once inside your cells, it doesn’t just deliver an instruction, it delivers the machinery to keep copying it.

Thank you to @cure345 for spotlighting Replicate among the companies shaping the future of mRNA vaccines.

https://t.co/K1ihXxccyL

[Replicate Bioscience, Inc. @Replicate_Bio]

Proud to be named one of @FastCompany's 2026 Most Innovative Companies.

From rabies, to RSV combination vaccines, to obesity - our srRNA platform is changing what’s possible in medicine at a fraction of the dose.

Read more about this year’s winners: https://t.co/KOK8Vk3fRw

[Replicate Bioscience, Inc. @Replicate_Bio]

Malaria and HIV remain urgent global health challenges. We are honored to partner with the @gatesfoundation to advance new srRNA vaccine candidates designed specifically for impact in low- and middle-income countries.

Read more: https://t.co/34BIOVc3it

[Replicate Bioscience, Inc. @Replicate_Bio]

We are thrilled to appoint Kathy Fernando, Ph.D., as CBO.

With nearly 20 years of experience, including leadership roles at Pfizer & Deloitte, she joins to help accelerate our pipeline and bring #srRNA therapies to patients worldwide.

Read more: https://t.co/KJexKXw2OJ

[Replicate Bioscience, Inc. @Replicate_Bio]

Today we announced the publication of our Phase 1 trial for RBI-4000, our #srRNA rabies vaccine, in @CommsMedicine. Results show durability 6x greater than standard vaccines - a first for #RNA.

Learn more: https://t.co/HM2pU5RKaL

[Replicate Bioscience, Inc. @Replicate_Bio]

We’re kicking off September at #RNALeaders USA Congress – where CEO Nathaniel Wang will speak to the advantages of srRNA, including durability.

We look forward to discussing Replicate’s latest progress, as well as the advantages of srRNA - we hope to see you there!

[Replicate Bioscience, Inc. @Replicate_Bio]

Big news today: Replicate enters a $550M+ exclusive deal with @novonordisk

Together, we’ll advance our self-replicating RNA (srRNA) technology for obesity, type 2 diabetes, and cardiometabolic disease. A milestone moment for RNA therapeutics.

Read more: https://t.co/Oi5mqBBn9x

[Replicate Bioscience, Inc. @Replicate_Bio]

Today we announced a paper in @NatureComms highlighting our Phase I clinical study of RBI-4000 an #srRNA rabies #vaccine. Results suggest RBI-4000 could offer much needed treatment option for #rabies. Congratulations to all who contributed to this work!

https://t.co/jYZZOe0Hkw

[Replicate Bioscience, Inc. @Replicate_Bio]

Replicate CEO Nathaniel Wang and CBO Rachael Lester will be at the @Piper_Sandler 36th Annual Healthcare Conference held December 3-5 in NYC. Reach out to schedule 1:1s and hear more about our latest company updates - we hope to see you there!

#srRNA #biotech #mRNA #RNA #vaccine

[Replicate Bioscience, Inc. @Replicate_Bio]

Don’t miss our presentation today at the 12th International #mRNA Health Conference. Our Head of R&D, Parinaz (Paris) Aliahmad, will share data from our rabies clinical trial showing the expanded therapeutic index of a novel, optimized #srRNA #vaccine.

#Biotech #RNA

[Replicate Bioscience, Inc. @Replicate_Bio]

On November 14th, our CBO Rachael Lester will participate in a roundtable hosted by @FT focused on funding biopharma innovation to discuss asset development and corporate growth in a complex and evolving macroeconomic environment.

#Biotech #BusinessDevelopment #Industry

[Replicate Bioscience, Inc. @Replicate_Bio]

Mark your calendar: Next week, our Head of Research & Development, Parinaz (Paris) Aliahmad, will present clinical data demonstrating the expanded therapeutic index of a novel #srRNA #vaccine at the 12th International #mRNA Health Conference. We hope to see you there!

[Replicate Bioscience, Inc. @Replicate_Bio]

Next week, Replicate will attend the DCVMN International 25th Annual General Meeting. We look forward to insightful discussions on prioritizing accessibility in #vaccine development, manufacturing, and roll out to ensure that scientific advancements benefit all populations.

#RNA

[Replicate Bioscience, Inc. @Replicate_Bio]

Our CBO Rachael Lester will be in NYC next week to present at the Oppenheimer Private Healthcare Company Showcase. Reach out to schedule meetings and learn how we’re expanding the utility of #RNAtherapeutics with our next generation #srRNA vectors.

#biotech #mRNA #vaccine

[Replicate Bioscience, Inc. @Replicate_Bio]

San Diego is a true hub of scientific innovation and a premier location for #RNATherapeutics R&D!
@CONNECTinSD 3rd Annual Innovation Day, our CDO and Co-founder Andrew Geall will showcase the positive impact of #RNA medicines on public health.

#srRNA #Biotech #SanDiego #IDSD24

[Replicate Bioscience, Inc. @Replicate_Bio]

Join our CEO Nathaniel Wang and CBO Rachael Lester for a fireside chat at the @MorganStanley 22nd Annual Global Healthcare Conference on September 6th.

We look forward to engaging discussions and collaborations that shape the future of #RNATherapies!

#RNA #srRNA #mRNA #vaccine

[Replicate Bioscience, Inc. @Replicate_Bio]

Come see us in San Diego for the #RNALeaders USA Congress! Today, our CEO @nathanielswang will discuss scaling strategies for #RNAtherapies during a keynote panel before presenting on key improvements enabled by our #srRNA technology in the afternoon.

#mRNA #RNA #vaccine

[Replicate Bioscience, Inc. @Replicate_Bio]

If you’re attending, our CEO Nathaniel Wang and CBO Rachael Lester will be onsite to discuss Replicate’s progress and the partnership opportunities using Replicate’s groundbreaking srRNA platform for vaccines and therapeutic proteins. We hope to see you there!

[Replicate Bioscience, Inc. @Replicate_Bio]

We’re looking forward to engaging with the #biotech and #pharma partnering community next week in San Diego at #BIO2024! https://t.co/px0TLdqb68

[Replicate Bioscience, Inc. @Replicate_Bio]

Join Andy Geall onsite at #TIDESUSA, where he is moderating a panel highlighting the next chapter of mRNA-based medicines and the broad utility of the field in addressing current hurdles in infectious disease and other therapeutic areas.